Publications by authors named "A Chiricozzi"
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition that can have a negative impact on a patient's quality of life. Long-term effectiveness is required to manage the symptoms of AD (skin inflammation, eczematous lesions, and itching). Because some of the systemic immunosuppressants used to treat AD have been associated with serious adverse events (AEs), other safer, more effective options, including dupilumab, have been proven effective long-term for treatment of adult and adolescent patients with moderate-to-severe AD.
View Article and Find Full Text PDFHidradenitis suppurativa (HS) is a chronic inflammatory disease that affects intertriginous skin areas, clinically characterized by recurrent inflamed nodules, abscesses, sinus tracts, and severe scars. Systemic treatments may provide temporary relief, while wide surgical excision offers prolonged disease-free periods. We evaluated the most efficient wound closure methods following wide excision of HS lesions in terms of recurrence, functionality, and quality of life.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates the prevalence of risk factors associated with oral Janus kinase inhibitors (JAKis) in patients with chronic hand eczema (CHE), highlighting concerns due to their black-box warnings for infections, cancer, and cardiovascular issues.
- - In a cohort of 941 CHE patients, 81.6% possessed at least one risk factor, with the majority being nonmodifiable; common risks included heavy smoking, obesity, hypercholesterolemia, and hypertension.
- - The findings suggest that healthcare providers should carefully evaluate these risk factors when considering oral JAKi treatments for CHE, as most patients have conditions that could complicate their use.
Psoriasis is a chronic, immune-mediated, inflammatory skin disease, associated with multiple comorbidities and psychological and psychiatric disorders. The quality of life of patients with this disease is severely compromised, especially in moderate-to-severe plaque psoriasis. Secukinumab, a fully humanized monoclonal antibody, was the first anti-interleukin (IL)-17 biologic approved for treating psoriasis.
View Article and Find Full Text PDFArticle Synopsis
- Prurigo nodularis (PN) is a chronic skin condition causing severe itching, and this study aimed to assess its impact on healthcare costs and resource use in Italy.
- The research analyzed data from 295 hospitalized PN patients and matched them with 590 non-PN individuals, revealing significant differences in comorbidities and healthcare resource consumption over a one-year follow-up period.
- PN patients had much higher healthcare costs, averaging €3847 compared to €711 for non-PN controls, primarily due to increased medication prescriptions, hospitalizations, and outpatient services.